- Home
- GLMD vs PPBT Comparison
GLMD vs PPBT Comparison
Compare GLMD & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLMD
- PPBT
- Stock Information
- Founded
- GLMD 2000
- PPBT 2010
- Country
- GLMD Israel
- PPBT Israel
- Employees
- GLMD N/A
- PPBT N/A
- Industry
- GLMD Biotechnology: Pharmaceutical Preparations
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- GLMD Health Care
- PPBT Health Care
- Exchange
- GLMD Nasdaq
- PPBT Nasdaq
- Market Cap
- GLMD 6.6M
- PPBT 7.4M
- IPO Year
- GLMD 2014
- PPBT N/A
- Fundamental
- Price
- GLMD $1.18
- PPBT $0.80
- Analyst Decision
- GLMD Hold
- PPBT Strong Buy
- Analyst Count
- GLMD 1
- PPBT 1
- Target Price
- GLMD N/A
- PPBT $33.00
- AVG Volume (30 Days)
- GLMD 65.7K
- PPBT 21.7M
- Earning Date
- GLMD 11-14-2025
- PPBT 11-06-2025
- Dividend Yield
- GLMD N/A
- PPBT N/A
- EPS Growth
- GLMD N/A
- PPBT N/A
- EPS
- GLMD N/A
- PPBT N/A
- Revenue
- GLMD N/A
- PPBT N/A
- Revenue This Year
- GLMD N/A
- PPBT N/A
- Revenue Next Year
- GLMD N/A
- PPBT N/A
- P/E Ratio
- GLMD N/A
- PPBT N/A
- Revenue Growth
- GLMD N/A
- PPBT N/A
- 52 Week Low
- GLMD $1.15
- PPBT $0.53
- 52 Week High
- GLMD $3.61
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- GLMD 32.65
- PPBT 50.37
- Support Level
- GLMD $1.16
- PPBT $0.71
- Resistance Level
- GLMD $1.27
- PPBT $0.89
- Average True Range (ATR)
- GLMD 0.08
- PPBT 0.12
- MACD
- GLMD -0.02
- PPBT 0.02
- Stochastic Oscillator
- GLMD 0.00
- PPBT 25.71
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.